Figure 2From: Clinical course of chronic hepatitis B patients who were off-treated after lamivudine treatment: analysis of 138 consecutive patientsClinical courses of initial HBeAg-positive patients after lamivudine cessation. Virologic relapse (A), biochemical breakthrough (B), hepatitis flare (C), and HBeAg reversion (D). Patients were grouped according to serum HBV DNA level and HBeAg status at cessation of lamivudine treatment: Group A, HBV DNA <50 copies/mL with HBeAg loss; Group B, HBV DNA 50-104 copies/mL with HBeAg loss; Group C, HBV DNA 50-104 copies/mL without HBeAg loss; Group D, HBV DNA ≥104 copies/mL irrespective HBeAg loss.Back to article page